RVMD FDA approval for RASONQUE in metastatic pancreatic cancer
RVMD received FDA approval for RASONQUE, a first-in-class RAS inhibitor, for metastatic pancreatic cancer following Phase 3 results.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.